An economic evaluation of radiotherapy for patients with symptomatic Ledderhose disease

Anneke de Haan*, Henk Groen, Johanna G.H. van Nes, M. Willemijn Kolff, Peter Paul van der Toorn, A. Helen Westenberg, Paul M.N. Werker, Johannes A. Langendijk, Roel J.H.M. Steenbakkers

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

35 Downloads (Pure)

Samenvatting

BACKGROUND: Evidence for effectiveness of radiotherapy for Ledderhose disease was demonstrated in the LedRad-study. However, the health economic impact of Ledderhose disease is unclear. Therefore, an economic evaluation alongside the LedRad-study was planned.

METHODS: The economic evaluation was performed as a cost-effectiveness and cost-utility analysis from the societal perspective. Primary outcome parameters were pain burden and Quality Adjusted Life Years (QALY), until 12 months after the end of treatment. Secondary analyses were performed with outcomes until 18 months. Incremental cost-effectiveness (ICER) and cost-utility ratios (ICUR) were calculated to express costs per unit improvement in pain burden and costs per QALY gained, for radiotherapy compared to sham-radiotherapy. Bootstrap replication was used to assess uncertainty surrounding the ratios and to construct cost-effectiveness acceptability curves for QALY gain.

RESULTS: Previous analysis showed a statistically significant improvement in pain- and QoL scores in favour of radiotherapy at 12 and 18 months. At these timepoints and excluding treatment costs, cumulative total costs were considerably lower in the radiotherapy group. The ICER until 12 months after treatment was 4987 euro per unit of pain burden reduction. The ICUR was 14249 euro per QALY gained. Most of the bootstrap replications were in the upper right quadrant, indicating that health gain can be achieved at higher costs. At increasing levels of willingness to pay for a gain in QALY, the probability of cost-utility gradually increased to approximately 85%.

CONCLUSIONS: In patients with symptomatic Ledderhose disease, radiotherapy, at a moderate threshold for willingness to pay, is cost-effective in terms of QoL gain.

TRIAL REGISTRATION NUMBERS: NCT03507010, NL62429.042.17.

Originele taal-2English
Artikelnummer109890
Aantal pagina's7
TijdschriftRadiotherapy and Oncology
Volume188
Vroegere onlinedatum31-aug.-2023
DOI's
StatusPublished - nov.-2023

Vingerafdruk

Duik in de onderzoeksthema's van 'An economic evaluation of radiotherapy for patients with symptomatic Ledderhose disease'. Samen vormen ze een unieke vingerafdruk.

Citeer dit